Dr. Katie Murray, DO, MS, SACS
Claim this profileUniversity of Missouri - Ellis Fischel
Studies Bladder Cancer
Studies Cancer
6 reported clinical trials
20 drugs studied
Area of expertise
1Bladder Cancer
Stage II
Stage I
DDR gene negative
2Cancer
Stage II
Stage I
DDR gene negative
Affiliated Hospitals
Clinical Trials Katie Murray, DO, MS, SACS is currently running
Standard Therapy + Surgery/Radiation
for Prostate Cancer
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Recruiting2 awards Phase 330 criteria
Pembrolizumab + Gemcitabine
for Bladder Cancer
This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment. Chemotherapy drugs, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the patient's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding pembrolizumab to gemcitabine may delay the return of BCG-unresponsive bladder cancer for longer period compared to gemcitabine alone.
Recruiting1 award Phase 223 criteria
More about Katie Murray, DO, MS, SACS
Clinical Trial Related2 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Katie Murray, DO, MS, SACS has experience with
- Gemcitabine Hydrochloride
- UGN-102
- Perioperative Pregabalin
- Pembrolizumab
- Cisplatin
- Triptorelin
Breakdown of trials Katie Murray, DO, MS, SACS has run
Bladder Cancer
Cancer
Transitional Cell Carcinoma
Prostate Cancer
Postoperative Pain
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Katie Murray, DO, MS, SACS specialize in?
Katie Murray, DO, MS, SACS focuses on Bladder Cancer and Cancer. In particular, much of their work with Bladder Cancer has involved Stage II patients, or patients who are Stage I.
Is Katie Murray, DO, MS, SACS currently recruiting for clinical trials?
Yes, Katie Murray, DO, MS, SACS is currently recruiting for 3 clinical trials in Columbia Missouri. If you're interested in participating, you should apply.
Are there any treatments that Katie Murray, DO, MS, SACS has studied deeply?
Yes, Katie Murray, DO, MS, SACS has studied treatments such as Gemcitabine Hydrochloride, UGN-102, Perioperative Pregabalin.
What is the best way to schedule an appointment with Katie Murray, DO, MS, SACS?
Apply for one of the trials that Katie Murray, DO, MS, SACS is conducting.
What is the office address of Katie Murray, DO, MS, SACS?
The office of Katie Murray, DO, MS, SACS is located at: University of Missouri - Ellis Fischel, Columbia, Missouri 65212 United States. This is the address for their practice at the University of Missouri - Ellis Fischel.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.